Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2007

View Archived Issues

CP-4126 well tolerated in solid tumor patients

Orphan Europe seeks EMEA approval of Vedrop for vitamin E deficiencies

Desvenlafaxine improves hot flushes, mood in postmenopausal women

Alcon submits amendment to NDA for Patanase

Lupin acquires majority stake in Kyowa

Wyeth and Zealand begin phase I trials on ZP-1609

FDA grants orphan drug status to recombinant fibrinogen

Enrollment complete for phase III clinical trial of pravastatin combination therapy

FDA denies approval of CX-717 clinical trials for ADHD

Affymax begins patient dosing in phase III trial of Hematide

Partial response rate reported in Davant phase II trial for colorectal cancer

Momenta evaluates M-118 in broad ACS clinical program

NS-1738, an allosteric modulator of alpha7 nAChRs improves short- and long-term memory in vivo

Phase III study of Gattex demonstrates clinical benefits

Series B financing by Metastatix to support cancer drug clinical trials

SpirH begins phase II study and opens enrollment for worldwide clinic participation

NPS sells mGluR collaboration assets to AstraZeneca

Novel NO donor shows potential in inflammatory skin conditions

Doribax approved by FDA for the treatment of cIAI and cUTI

Gilead submits marketing applications for Viread in U.S. and E.U.

NDA for Ampligen submitted by Hemispherx Biopharma

FDA approves use of Lexiva with reduced dose of ritonavir

Clinical data on PEP-005 topical gel for skin cancers presented

Recent Janssen and Astellas patents report novel therapeutic agents for thrombotic disorders

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents describe new treatment options for cardiovascular disorders

The ACAT inhibitor KY-382 shows antiatherosclerotic effects in rabbits

Tamoxifen for the treatment of acute mania / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...